JP2014507435A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507435A5
JP2014507435A5 JP2013553604A JP2013553604A JP2014507435A5 JP 2014507435 A5 JP2014507435 A5 JP 2014507435A5 JP 2013553604 A JP2013553604 A JP 2013553604A JP 2013553604 A JP2013553604 A JP 2013553604A JP 2014507435 A5 JP2014507435 A5 JP 2014507435A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013553604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507435A (ja
JP6178241B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024697 external-priority patent/WO2012109567A2/en
Publication of JP2014507435A publication Critical patent/JP2014507435A/ja
Publication of JP2014507435A5 publication Critical patent/JP2014507435A5/ja
Application granted granted Critical
Publication of JP6178241B2 publication Critical patent/JP6178241B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013553604A 2011-02-11 2012-02-10 血管新生障害の処置 Expired - Fee Related JP6178241B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441738P 2011-02-11 2011-02-11
US61/441,738 2011-02-11
PCT/US2012/024697 WO2012109567A2 (en) 2011-02-11 2012-02-10 Treatment of angiogenesis disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017136730A Division JP6633029B2 (ja) 2011-02-11 2017-07-13 血管新生障害の処置

Publications (3)

Publication Number Publication Date
JP2014507435A JP2014507435A (ja) 2014-03-27
JP2014507435A5 true JP2014507435A5 (2) 2015-04-09
JP6178241B2 JP6178241B2 (ja) 2017-08-09

Family

ID=46639221

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013553604A Expired - Fee Related JP6178241B2 (ja) 2011-02-11 2012-02-10 血管新生障害の処置
JP2017136730A Active JP6633029B2 (ja) 2011-02-11 2017-07-13 血管新生障害の処置
JP2019223678A Active JP7053559B2 (ja) 2011-02-11 2019-12-11 血管新生障害の処置
JP2022060499A Active JP7536049B2 (ja) 2011-02-11 2022-03-31 血管新生障害の処置

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017136730A Active JP6633029B2 (ja) 2011-02-11 2017-07-13 血管新生障害の処置
JP2019223678A Active JP7053559B2 (ja) 2011-02-11 2019-12-11 血管新生障害の処置
JP2022060499A Active JP7536049B2 (ja) 2011-02-11 2022-03-31 血管新生障害の処置

Country Status (7)

Country Link
US (6) US8980261B2 (2)
EP (3) EP3604534A1 (2)
JP (4) JP6178241B2 (2)
CA (2) CA2841404C (2)
DK (1) DK2673363T3 (2)
ES (2) ES2645366T3 (2)
WO (1) WO2012109567A2 (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2645366T3 (es) 2011-02-11 2017-12-05 The Rockefeller University Tratamiento de trastornos de la angiogénesis
TWI465241B (zh) * 2012-12-19 2014-12-21 Ind Tech Res Inst 圓柏(Juniperus chinensis)萃取物或木酚素(lignan)用於製造抑制血管新生之藥物的用途
HUP1300509A2 (hu) * 2013-08-30 2015-03-30 Gabor Firneisz CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásra
ES2688737A1 (es) * 2017-05-04 2018-11-06 Universidad Del País Vasco / Euskal Herriko Unibertsitatea Método para diagnosticar placa ateroesclerótica inestable
EP3823982A4 (en) * 2018-07-17 2022-04-13 Helixmith Co., Ltd Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
MA55080A (fr) * 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
CN111808938A (zh) * 2019-04-11 2020-10-23 南方医科大学南方医院 Atp6v0d2用于动脉粥样硬化的早期诊断或疗效监控
JP7817766B2 (ja) 2022-05-31 2026-02-19 吉野石膏株式会社 建物壁
WO2025217863A1 (zh) * 2024-04-18 2025-10-23 苏州鲲石一号生物科技有限公司 Gas6融合蛋白及其制备方法与应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0870057B1 (en) * 1995-11-16 2003-09-24 The Baylor College Of Medicine Method for identifying metastatic sequences
EP1062340A2 (en) * 1998-03-13 2000-12-27 The Baylor College of Medicine Compositions and methods for the treatment and prevention of metastatic disorders
US8257750B2 (en) 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
AU2001290920B2 (en) * 2000-09-14 2006-11-23 The University Of British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
JP4717633B2 (ja) 2002-08-21 2011-07-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 癌関連タンパク質を標的とするRNAiプローブ
DE602004025706D1 (2) 2003-07-10 2010-04-08 Central Inst Exper Animals
WO2005059109A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
FR2865736B1 (fr) 2004-02-02 2006-07-14 Synt Em Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
AU2006203974A1 (en) * 2005-01-06 2006-07-13 Aveo Pharmaceuticals, Inc. Target validation assay
AU2006228989B2 (en) * 2005-03-30 2012-06-14 Murdoch Childrens Research Institute Methods and agents for modulating cellular activity
WO2007056604A2 (en) * 2005-11-09 2007-05-18 Irm Llc Methods and compositions for modulating cell motility and inhibiting tumor metastasis
WO2008073660A1 (en) 2006-11-09 2008-06-19 University Of Washington Molecules and methods for treatment and detection of cancer
ES2572356T3 (es) 2007-11-09 2016-05-31 Peregrine Pharmaceuticals Inc Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
WO2009082744A2 (en) 2007-12-22 2009-07-02 Sloan-Kettering Institute For Cancer Research Prognosis and interference-mediated treatment of breast cancer
US9179654B2 (en) * 2008-04-07 2015-11-10 Cornell Research Foundation, Inc. Inhibition of angiogenesis
AU2009242126B2 (en) * 2008-04-29 2014-03-27 Pharnext New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis
WO2009154790A2 (en) * 2008-06-20 2009-12-23 University Of Massachusetts Novel metastasis suppresor genes and uses thereof
JPWO2010064702A1 (ja) 2008-12-05 2012-05-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー
WO2011011061A2 (en) * 2009-07-21 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy
ES2645366T3 (es) * 2011-02-11 2017-12-05 The Rockefeller University Tratamiento de trastornos de la angiogénesis

Similar Documents

Publication Publication Date Title
JP2014507435A5 (2)
JP2017508475A5 (2)
JP2016537383A5 (2)
PH12015501505B1 (en) Antibodies that bind to tl1a and their uses
EA201791093A1 (ru) Антитела к cd47, способы и применение
JP2013538057A5 (2)
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
JP2014205674A5 (2)
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
WO2013173496A3 (en) Cd33 antibodies and use of same to treat cancer
MX369148B (es) Agentes de unión kir3dl2.
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
RU2017129721A (ru) АНТИТЕЛА ПРОТИВ αβTCR
WO2012135854A3 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
JP2014526898A5 (2)
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
MX383543B (es) Anticuerpo anti-calicreina-2 humanizado.
NZ728016A (en) Novel modulators and methods of use
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
CY1122132T1 (el) Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof